Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
head and neck cancer
Biotech
Inhibrx says OX40 agonist’s durability confirmed by ph. 2 win
Inhibrx’s CEO argued that the 9.6 months of PFS demonstrated by its OX40 agonist has proven the therapy’s durability in treating head and neck cancer.
Will Maddox
Sep 8, 2026 10:22am
Inhibrx’s OX40-Keytruda combo shows promise in early ph. 2 data
May 11, 2026 10:06am
Rakuten lights path to 2028 FDA filing with fresh $100M raise
Jan 7, 2026 9:43am
Nykode bets future on cancer trial after losing Genentech pact
Aug 27, 2025 8:25am
PDS reports 39 months OS in phase 2 head and neck cancer trial
Aug 25, 2025 9:00am
Bicara CEO: ASCO data resonate more with 'people that matter'
Jun 2, 2025 4:26pm
